

Lipum AB (publ) comment on mandatory bid from Flerie Invest AB

Lipum AB's (publ) ("Lipum") main owner Flerie Invest AB ("Flerie") announced on 1 March 2024 that it has acquired an additional 859 shares in Lipum and that Flerie thereafter owns a total of 2,981,553 shares in Lipum, corresponding to approximately 32.01 per cent of the total number of shares and votes in Lipum.

Through its acquisition on 1 March 2024, Flerie passed the threshold for a mandatory bid according to the Takeover rules for certain trading platforms. Today, on 6 March 2024, Flerie announced a mandatory bid offer of SEK 6.60 per share to the shareholders of Lipum (the "Offer") and published an offer document relating to the Offer. The acceptance period for the Offer is expected to commence on 7 March 2024 and expire around 4 April 2024. For further information, please refer to [Flerie's press release](#) and to the offer document relating to the Offer which is available on Hagberg Aneborn's website www.hagberganeborn.se and Flerie's website www.flerie.com.

The Board of Directors will evaluate the Offer and obtain a so-called fairness opinion. A statement on the Board of Directors' attitude to the Offer is intended to be announced well in advance of the expiry of the applicable acceptance period according to the Offer.

The board member Carl-Johan Spak will, due to his role as Senior Advisor to Flerie, not participate in the Board of Directors' handling of or decisions on matters related to the Offer.

Contacts

Ola Sandborgh, CEO
ola.sandborgh@lipum.se
+46 72 218 80 21
Web: www.lipum.se

About Us

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

PRESS RELEASE

06 March 2024 19:20:00 CET



Attachments

[Lipum AB \(publ\) comment on mandatory bid from Flerie Invest AB](#)